BIMZELX

GrowthmAb

bimekizumab

BLAINJECTIONINJECTABLE
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Bimekizumab-bkzx is a humanized immunoglobulin IgG1/ κ monoclonal antibody with two identical antigen binding regions that selectively bind to human interleukin 17A (IL-17A), interleukin 17F (IL-17F), and interleukin 17-AF cytokines, and inhibits their interaction with the IL-17 receptor complex.…

Clinical Trials (5)

NCT07290036Phase 1Recruiting

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

Started Dec 2025
392 enrolled
Psoriatic ArthritisAxial Spondyloarthritis
NCT07219420Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

Started Nov 2025
300 enrolled
Palmoplantar Pustulosis
NCT06888193Phase 1Recruiting

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Started Nov 2025
20 enrolled
Moderate to Severe Plaque PsoriasisPsoriatic ArthritisAxial Spondyloarthritis+1 more
NCT06921850Phase 3Recruiting

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

Started Apr 2025
40 enrolled
Hidradenitis Suppurativa
NCT06668181Phase 3Recruiting

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Started Mar 2025
40 enrolled
Enthesitis-related ArthritisJuvenile Psoriatic Arthritis